Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes

Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes

April 30, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that Acceleron and its collaboration partner, Celgene Corporation, plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015. The companies will continue to develop sotatercept for patients with chronic kidney disease.

Eleven Biotherapeutics Publishes Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis

Eleven Biotherapeutics Publishes Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis

April 29, 2015

Phase 2 Results Published in Eye and Contact Lens Demonstrate Statistically Significant and Clinically Meaningful

Improvements with EBI-005 and Support Planned Phase 3 Clinical Study Design

Agios Pharmaceuticals Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

Agios Pharmaceuticals Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

April 29, 2015

 Brain-penetrant, pan-IDH mutant inhibitor broadens pipeline for treatment of patients with IDH mutant positive cancers

Vic Myer, Ph.D. Joins Editas Medicine as Chief Technology Officer

Vic Myer, Ph.D. Joins Editas Medicine as Chief Technology Officer

April 27, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced the appointment of Vic Myer, Ph.D., as chief technology officer. Dr. Myer brings to Editas extensive experience in leading pharmaceutical and technology research and development, information technology and business development.

Blend Therapeutics Presents Preclinical Data for Lead Pentarin™ Program, BTP-277, Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer

Blend Therapeutics Presents Preclinical Data for Lead Pentarin™ Program, BTP-277, Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer

April 21, 2015

First Product from The Pentarin™ Platform, A Novel Class of Miniaturized Biologic Drug Conjugates (mBDCs) Incorporated in Nanoparticles

Data Presented at AACR Annual Meeting

BIND Therapeutics Presents Data Highlighting Ability of Accurins to Control Biodistribution and Accumulate in Target Tissue at AACR Annual Meeting 2015

BIND Therapeutics Presents Data Highlighting Ability of Accurins to Control Biodistribution and Accumulate in Target Tissue at AACR Annual Meeting 2015

April 22, 2015

- Studies from proprietary and collaboration programs show potential of Accurins as best-in-class targeted therapeutics -

- Data demonstrate optimized drug properties including improved therapeutic index, elevated accumulation in targeted tissue at tumor sites and sustained release -

Blend Therapeutics Presents Preclinical Data for Lead Candidate BTP-114 that Demonstrated Superiority to Cisplatin in Tumor Growth Inhibition

Blend Therapeutics Presents Preclinical Data for Lead Candidate BTP-114 that Demonstrated Superiority to Cisplatin in Tumor Growth Inhibition

April 21, 2015

BTP-114 Is a Novel, Personalized Cisplatin Prodrug with IND to be Filed in Q2 2015

Data Presented at AACR Annual Meeting

Eleven Biotherapeutics Presents Phase 2 Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis at ASCRS 2015 Annual Meeting

Eleven Biotherapeutics Presents Phase 2 Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis at ASCRS 2015 Annual Meeting

April 16, 2015

Data Demonstrated Statistically Significant Improvements in Ocular Itching, Ocular Tearing and Nasal Symptoms Associated with Allergic Conjunctivitis

Avedro Expands Patent Portfolio with Licenses from Caltech and IROC Innocross

Avedro Expands Patent Portfolio with Licenses from Caltech and IROC Innocross

April 14, 2015

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro Inc., a Boston-based ophthalmic pharmaceutical and medical device company announced today that it has significantly expanded its patent portfolio. Avedro obtained an exclusive license to a patent held by the California Institute of Technology in the field of corneal cross-linking using ultraviolet light. This method patent (U.S. Patent No. 8,414,911) covers two key cross-linking applications: accelerated cross-linking and corneal cross-linking used during refractive surgery.

Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer

Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer

April 13, 2015

Company to Accelerate Development of Cancer Product Pipeline, with Filing of IND for Lead Product Candidate in Q2 2015